Literature DB >> 24139211

Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.

Maryam Zenali1, Michael J Overman, Asif Rashid, Russell B Broaddus, Hua Wang, Matthew H Katz, Jason B Fleming, James L Abbruzzese, Huamin Wang.   

Abstract

Because of the rarity of duodenal adenocarcinoma (DAC), the clinicopathologic features and prognostication data for DAC are limited. There are no published studies directly comparing the prognosis of DAC to that of ampullary adenocarcinoma (AA) and of pancreatic ductal adenocarcinoma (PDA) after resection. In this study, we examined the clinicopathologic features of 68 patients with DAC, 92 patients with AA, and 126 patients with PDA who underwent resection. Patient clinicopathologic and survival information were extracted from medical records. Statistical analysis was performed using Statistical Package for the Social Sciences with 2-sided significance level of .05. Patients with DAC had higher American Joint Committee on Cancer (AJCC) stage than AA patients (P = .001). Lymph node metastasis (P = .013) and AJCC stage (P = .02) correlated with overall survival in DAC patients. Patients with DAC or AA had lower frequencies of lymph node metastasis and positive margin and better survival than those with PDA (P < .05). However, no differences in nodal metastasis, margin status, or survival were observed between DAC patients and those with AA. Our study showed that lymph node metastasis and AJCC stage are important prognostic factors for overall survival in DAC patients. Patients with DAC had less frequent nodal metastasis and better prognosis than those with PDA. There was no significant difference in prognosis between DAC and AA.
© 2013.

Entities:  

Keywords:  Ampullary adenocarcinoma; Duodenal adenocarcinoma; Pancreatic cancer; Prognosis; Survival

Mesh:

Year:  2013        PMID: 24139211      PMCID: PMC4378233          DOI: 10.1016/j.humpath.2013.07.030

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

1.  Small bowel cancer risk in Lynch syndrome.

Authors:  K Schulmann; C Engel; P Propping; W Schmiegel
Journal:  Gut       Date:  2008-11       Impact factor: 23.059

Review 2.  Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment.

Authors:  Thomas Aparicio; Aziz Zaanan; Magali Svrcek; Pierre Laurent-Puig; Nicolas Carrere; Sylvain Manfredi; Christophe Locher; Pauline Afchain
Journal:  Dig Liver Dis       Date:  2013-06-21       Impact factor: 4.088

3.  Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?

Authors:  M G Hurtuk; S Devata; K M Brown; K Oshima; G V Aranha; J Pickleman; M Shoup
Journal:  Am J Surg       Date:  2007-03       Impact factor: 2.565

4.  Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research.

Authors:  N Rotman; D Pezet; P L Fagniez; D Cherqui; B Celicout; P Lointier
Journal:  Br J Surg       Date:  1994-01       Impact factor: 6.939

5.  Racial and ethnic variation in the incidence of small-bowel cancer subtypes in the United States, 1995-2008.

Authors:  Marc T Goodman; Rayna K Matsuno; Yurii B Shvetsov
Journal:  Dis Colon Rectum       Date:  2013-04       Impact factor: 4.585

6.  Adenocarcinoma of the small intestine.

Authors:  K Ouriel; J T Adams
Journal:  Am J Surg       Date:  1984-01       Impact factor: 2.565

7.  Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.

Authors:  Aaron Struck; Thomas Howard; Elena G Chiorean; Jeffrey M Clarke; Robert Riffenburgh; Higinia R Cardenes
Journal:  J Surg Oncol       Date:  2009-08-01       Impact factor: 3.454

8.  Improving resectability and survival in patients with primary duodenal carcinoma.

Authors:  R Delcore; J H Thomas; J Forster; A S Hermreck
Journal:  Am J Surg       Date:  1993-12       Impact factor: 2.565

9.  Predictors of survival in periampullary cancers following pancreaticoduodenectomy.

Authors:  Ioannis Hatzaras; Nathaniel George; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2010-01-28       Impact factor: 5.344

10.  Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Authors:  M J Overman; J Pozadzides; S Kopetz; S Wen; J L Abbruzzese; R A Wolff; H Wang
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more
  4 in total

1.  Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.

Authors:  Yue Xue; Alessandro Vanoli; Serdar Balci; Michelle M Reid; Burcu Saka; Pelin Bagci; Bahar Memis; Hyejeong Choi; Nobuyike Ohike; Takuma Tajiri; Takashi Muraki; Brian Quigley; Bassel F El-Rayes; Walid Shaib; David Kooby; Juan Sarmiento; Shishir K Maithel; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

2.  Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes.

Authors:  Jana Tesarikova; Pavel Skalicky; Daniela Kurfurstova; Hana Svebisova; Ondrej Urban; Premysl Falt; Jana Zapletalova; Dusan Klos; Martin Lovecek
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2021-05-11       Impact factor: 1.648

Review 3.  Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer.

Authors:  Manju D Chandrasegaram; Anthony J Gill; Jas Samra; Tim Price; John Chen; Jonathan Fawcett; Neil D Merrett
Journal:  World J Gastrointest Oncol       Date:  2017-10-15

Review 4.  Current and Potential Applications of Artificial Intelligence in Gastrointestinal Stromal Tumor Imaging.

Authors:  Cai-Wei Yang; Xi-Jiao Liu; Si-Yun Liu; Shang Wan; Zheng Ye; Bin Song
Journal:  Contrast Media Mol Imaging       Date:  2020-11-26       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.